[Experimental survey of a new topical anti-oxidant based on furfuryl palmitate in the treatment of child's and baby's dermatitis with eczema: results from a multicenter clinical investigation].

In this paper we present the preliminary results of a multi-center clinical investigation carried out on a new topical product (Triderm(R) Lenil+) containing Superoxidodismutase (SOD), 18-beta glycyrrethic acid, Vitamin E, alpha bisabolol and a new patented antioxidant molecule, Furfuryl palmitate. These active agents altogether protect skin from cell damages that promote the inflammatory syndrome; their action is furthermore sustained by agents such as phytosphingosine and phytosterols that act to repair the skin barrier. Furfuryl palmitate is an ester with a strong quenching ability towards the singlet oxygene (1O2) and with a high permeability potential through the biological membranes, thanks to its lipophylic formula. Further than being among the main responsible for skin ageing, the 1O2 is involved in the genesis of many topical pathologies such as allergic and irritant dermatitis, atopic dermatitis, inflammation, psoriasis and sunburns. The product has been extensively tested for its effectiveness and skin tolerability on a selected population of 60 children and babies with age ranging from 2 months to 14 years, suffering mainly with atopic dermatitis and irritant dermatitis. The topical use of the product caused a significant improvement of the inflammatory skin conditions, with evident and fast inflammation and eczema reduction in all the investigated pathologies, as shown in the present study. The product has been formulated in order to avoid any sensitisation risk and did not show any relevant side effect. It is particularly suitable in the treatment of pediatric dermatitis with symptoms like eczema, itching, desquamation and xerosis.